Company Overview
Cardiff Oncology, Inc. operates as a clinical-stage biotechnology entity dedicated to developing novel therapeutic modalities for the treatment of various cancers within the United States. The company's primary focus is on advancing its lead drug candidate, Onvansertib, which functions as an oral and selective polo-like kinase 1 inhibitor specifically designed for treating RAS-mutated metastatic colorectal cancer. This enterprise functions within the Healthcare sector and the Biotechnology industry, positioning it as a specialized player in the pharmaceutical research and development landscape. As of the latest reporting period, the company maintains a market capitalization of $105.97M, generates annual revenue of $593,000, and employs a workforce of 30 individuals. The market cap figure relative to the annual revenue indicates that the company is valued significantly above its current sales output, a characteristic often observed in early-stage biotechnology firms where future clinical potential is priced rather than current profitability. The small employee count of 30 suggests a lean operational structure typical of clinical-stage companies that prioritize research and development over large-scale manufacturing or administrative overheads at this stage of their lifecycle.
Financial Health
The company reported a revenue of $593,000 over the trailing twelve months, while simultaneously recording a net income of $-45,876,000 and an EBITDA of $-48,596,000. The substantial gap between the minimal revenue and the significant negative net income reveals a cost structure dominated by research and development expenditures, clinical trial costs, and general administrative expenses that far outweigh current sales. Free cash flow stands at $-19,617,000, indicating that the company is burning cash at a rapid pace, which implies limited financial flexibility and a reliance on external capital sources to fund ongoing operations. Analysis of the three primary margin metrics shows a gross margin of 0.0%, an operating margin of -3221.0%, and a profit margin of 0.0%, all of which indicate that the company has not yet achieved commercial scale or cost efficiencies necessary for profitability in its current fiscal environment. The balance sheet holds $58.30M in cash against $832,000 in debt, resulting in a debt-to-equity ratio of 1.83, which suggests a balance sheet that is leveraged but not insolvent, given the substantial cash reserve relative to liabilities. The current ratio is listed at 3.67, indicating that the company possesses more than three times the current assets needed to cover its short-term liabilities, which points to adequate short-term liquidity despite the negative earnings. Return on Equity is -71.5% and Return on Assets is -38.5%, metrics that reveal that management effectiveness is currently measured by the erosion of shareholder and asset value rather than the generation of positive returns, a common trait for companies in the clinical development phase.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive net income, while the forward P/E is -2.21, implying that the market is pricing in future earnings that are currently projected to remain negative or are calculated based on negative earnings expectations. The price-to-book ratio is 2.33, indicating that the market values the company at a premium of roughly 133% over its book value, reflecting investor confidence in the potential of its pipeline despite current financial losses. Alternative valuation metrics such as the price-to-sales ratio of 178.69 and an EV/EBITDA of -1.00 suggest that the stock is priced almost entirely on speculative growth potential rather than sales volume or operational earnings. The 52-week high is $4.56 and the 52-week low is $1.48, meaning the current trading price sits somewhere within this range, though the specific current price point is not provided in the available facts to calculate the exact percentage deviation from the high or low. The beta value is 1.37, which means the stock price is expected to be 37% more volatile than the broader market, exposing investors to higher risk fluctuations relative to large-cap benchmarks.
Growth & Income
Revenue growth year-over-year is 60.9%, whereas earnings growth is N/A, indicating that while the top line is expanding rapidly, the company is still in a phase where revenue does not yet translate into profitability, a typical trajectory for clinical-stage biotechnology firms. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the firm reinvests all available resources and retained earnings into research, development, and clinical trials rather than distributing income to shareholders. The overall growth and income profile is characterized by high revenue expansion rates coupled with significant cash burn and no current dividend income, reflecting a strategy focused on long-term asset accumulation through drug development rather than immediate shareholder returns.